Endo, Jubilant Expand Oncology Discovery Partnership

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Sri(dhar) Mosur, CEO and president of global drug discovery and development at Jubilant, said: “We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant’s focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide.”

Ivan Gergel, executive vice president of R&D at Endo, said: “We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program. Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo’s pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts.”